Upcoming Conferences & Presentations

A regularly invited speaker at major international conferences, I also chair key presentation sessions and organize high level topical symposia. My ambitious schedule (see below) recognizes the urgency of my scientific mission, my dedication to the effective dissemination of scientific results, and my value in R&D strategy and policy formulation.

Following is a list of my upcoming events. For my previous activities see the list of prior events that I’ve presented at and/or organized.

June 2016
16-20 June, Boston, USA
U. Theuretzbacher: WS – Introduction to Pharmacodynamics
May 2016
2-3 June, Amsterdam, NL
U. Theuretzbacher: Panel discussion – The way forward
May 2016
4-7 May, Dubai, UAE
U. Theuretzbacher: New Molecules against resistant Pseudomonas aeruginosa
U. Theuretzbacher: Worldwide initiative to control AMR and role of Anti-microbial stewardship
April 2016
24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
9-12 April, Amsterdam, NL
U. Theuretzbacher: What other new antibiotics will soon come to market?
March 2016
February 2016
22-23 February, Bielefeld, Germany

U. Theuretzbacher: Forschungslücken schließen

Febbruary 2016
10 February 2016,  The Wellcome Trust, London

U. Theuretzbacher: A withering vine or golden opportunity? The changing face of the global research and development landscape

September 2015
27-29 September, San Francisco, CA, USA
Symposium 1: Reviving old antibiotics: Applying new PK/PD strategies
U. Theuretzbacher: How Do You “Re-develop” an Old Antibiotic? Experience from the Publicly Funded Multinational Project AIDA
27 September, 8:00 AM-12:00 PM
September 2015

22-24 September, San Diego, CA, USA
U. Theuretzbacher: Policy actions since the Prato conference
Thursday 24 September 2015

September 2015
September 17-21, 2015, San Diego, CA, USA
Workshop Thursday, Sep 17, 2015, 8:30 AM -12:00 PM
Introduction to Pharmacokinetics/Pharmacodynamics
U. Theuretzbacher: Workshop Convener,
Presentation: Introduction to Pharmacodynamics
April 2015
23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) Copenhagen, 25-28 April2015
U. Theuretzbacher: Drug pipeline for Gram-negative bacteria
15 April, 13:30
March 2015

International Congress of the Asia Pacific Society of Infection Control
26-29 March 2015

U. Theuretzbacher: Stewardship strategies to control MDRO

March 2015

13. Symposium Infektionsmedizin in Tübingen, Germany, 7 March 2015

U. Theuretzbacher: Neue Antibiotika für gramnegative Bakterien

February 2015
Meeting the challenge of antimicrobial resistance: Working together across political, professional and public fronts
Thursday 5 February 2015

U. Theuretzbacher: The changing face of pharma industry research

October 2014

ESCMID Conference

Reviving Old Antibiotics

22 – 24 October 2014, Vienna, Austria

U. Theuretzbacher: Scientific organiser

U. Theuretzbacher: How do you “re-develop” an old antibiotic: experience from AIDA

October 2014

ESCMID Postgraduate Education Course

Infection Management in the Elderly: A Wide Room for Improvement

2 – 3 October 2014, Annecy, France

U. Theuretzbacher: General principles of PK/PD
September 2014

55th ICAAC

September 5-9, 2014, Washington DC, USA

Workshop Monday, Sep 05, 2014, 8:30 AM -12:30 PM
Introduction to Pharmacokinetics/Pharmacodynamics
U. Theuretzbacher: Workshop Convener,
Presentation: Introduction to Pharmacodynamics

August 2014

Educational Workshop

Bringing PK and PD into the Clinic

21 August 2014, Medical University Innsbruck, Austria

July 2014

ESCMID Postgraduate Education Course

Bringing PK and PD in Fungal Infections into the Clinic

4 – 6 July 2014, Nijmegen, The Netherlands

U. Theuretzbacher: General principles of PK/PD.

May 2014

23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
10-13 May, Barcelona, Spain

  • 2-hour Educational Workshop
    10 May 2014, 08:45 – 10:45
    Basic concepts of pharmacokinetics and pharmacodynamics

U. Theuretzbacher: Optimising therapy to minimise emergence of resistance.

  • Official Symposium: The Good, the Bad and the Ugly: recently approved and developmental anti-bacterials

U. Theuretzbacher: Developmental beta-lactamase inhibitors in phase 2/3 clinical trials.

April 2014

International Congress on Infectious Diseases (ICID)
April 2-5, 2014, Cape Town, South Africa

Symposium: Nosocomial Infections in Low and Middle Income Countries
U. Theuretzbacher: Global Resistance hot spots – role of low and middle income countries

December 2013

Symposium Dec 7, 9:00-10:30 AM
Antibiotische und nichtantibiotische Therapie von Infektionen
U. Theuretzbacher: Neues zu Colistin und anderen älteren Antibiotika

September 2013

53rd ICAAC
September 10-13, 2013, Denver, Colorado, USA

Workshop Monday, Sep 09, 2013, 8:30 AM -12:30 PM
Introduction to Pharmacokinetics/Pharmacodynamics
U. Theuretzbacher: Workshop Convener,
Presentation: Introduction to Pharmacodynamics

June 2013

28th International Congress of Chemotherapy and Infection
5th to 8th June 2013 in Yokohama, Japan

Official Symposium, 7th June, 16:00-17:30
U. Theuretzbacher: Facilitating new drug development – international actions.

May 2013 1st International Conference on Polymyxins2 – 4 May, 2013, Monash Centre in Prato, Italy

  • Session, 2 May, 16:15 – 18:00
    What is the role of inhaled polymyxins for treatment of lung infections?
    Chair: Keith Kaye, Ursula Theuretzbacher
  • Session, 4 May, 11:00 – 12:30
    The Prato Polymyxin Consensus
April 2013

23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
27th – 30th April, Berlin, Germany

U. Theuretzbacher: Impact of resistance on treatment and dosing decisions.

  • Official Symposium: Pharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancer
    Chair: C. Viscoli, U. Theuretzbacher
    27 April 2013, 13:30 – 15:30

U. Theuretzbacher: Dosing considerations in cancer patients.

April 2013

Antimicrobial Stewardship in Hospitals, ESCMID Postgraduate Education Course
25 – 26 April 2013, Zeuthen near Berlin, Germany

U. Theuretzbacher: Improving dosing regimens to minimise resistance.

March 2013 Superbugs&Superdrugs– A Focus on Antibacterials March 4-5, 2013, 2012, London, UK
Session: Public/Private Partnerships

  • J. Larsen: Partnering and Working with BARDA
  • L. Matthiesen: New partnerships to combat antimicrobial resistance
  • U. Theuretzbacher: Publicly funded antibacterial drug development in Europe

Round Table Discussion: Richard Bax (TranScrip Partners), Richard Bergstrom (Director General, European Federation of Pharmaceutical Industries and Associations, EFPIA), Ursula Theuretzbacher (Center For Anti-Infective Agents), Line Matthiessen, Head of Infectious Diseases and Public Health Unit, European Commission).

4th World Annual PK/PD Summit  Nov 27-29, 2012, Frankfurt, GermanyWorkshop: Antimicrobial dose finding and optimising for early clinical studies of bacterial infections

  • How to more effectively translate animal PK/PD into humans to better determine an appropriate dosage regimen
  • Current updates on regulatory aspects related to PK/PD
  • Effective failure analysis of early PK/PD studies
  • Specific PK/PD considerations for treatment of urinary tract infections
  • Early phase I studies – What should be considered?
13th Asia-Pacific Congress of Clinical Microbiology and Infection(APCCMI)Oct 25-28, 2012, Beijing, ChinaSecuring New Antibiotics (co-organized by ISC Antibiotics of the Future WG)

  1. Facilitating new drug development, Ursula Theuretzbacher
  2. Do we need new antibiotics?-a paradox
  3. What is new in pipeline?
  4. New strategy for antimicrobial R&D
52nd ICAAC
8 – 12 Sept 2012, San Francisco, USA
Basics of Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents
Clinical Relevance of Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents
Post-ICAAC ISAP symposiumSept 12 2012, San Francisco, USA
ESCMID Summer School11th ESCMID Summer School,21 – 27 July 2012, Innsbruck, AustriaProgramme:U. Theuretzbacher: State-of-the-art therapy of serious Gram-positive bacterial infections, including MRSA.U. Theuretzbacher: Catheter-related infections: diagnosis and how to manage?U. Theuretzbacher: Surgical site infections, how can we prevent them?
First International Symposium on Enterobacteriaceae producing Carbapenemases
March 2, 2012, Paris, France
March 2012 Superbugs & Superdrugs – A Focus On Antibacterials,
March 6, 2012, London, UK
Special Workshop:
The Global Need for New Antibiotics – International Actions and Implications for Antibacterial Drug Development
Antibacterial Drug Development
Integrating Chemistry and Biology
April 17-18, 2012, San Diego, CA, USA.
U. Theuretzbacher: PK/PD and Emergence of Resistance
With antibiotic usage, emergence of resistance is unavoidable. However, several factors in the drug development process can be adjusted to reduce the risk of rapid emergence of resistance in clinical settings. During drug development, PK/PD models are appropriate tools for mitigating the risk of resistance.
My activities during the ECCMID 2012 in London, UK include:

ISAP/EPASG workshop:
Optimising treatment based on a pharmacodynamic approach: an interactive workshop using clinical cases
arranged with the ESCMID PK/PD of Anti-Infectives Study Group (EPASG)
Convenors: Ursula Theuretzbacher, Vienna, Austria & Johan Mouton, Nijmegen, Netherlands

  • Dosing and duration of treatment of aminoglycoside and glycopeptide therapy
  • Optimised dosing regimens for beta-lactams
  • Impact of resistance on treatment and dosing decisions
  • Dose adjustments in special patient populations
  • Combination treatment

William A. Craig, MD; Univ. of Wisconsin, Madison, WI.
Hartmut Derendorf, PhD; Univ. of Florida, Gainesville, FL.
Johan W. Mouton, PhD; Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands.
Ursula Theuretzbacher, PhD; Ctr. for Anti-Infective Agents, Vienna, Austria

Official Symposium

Update in drug development

– Antibacterial
Ursula Theuretzbacher, Vienna, Austria
– Antiviral
Johan Neyts, Leuven, Belgium
– Antifungal
Cornelia Lass-Floerl, Innsbruck, Austria
– Antiparasitic
Reto Brun, Basel, Switzerland

Oral Session

Considering pharmacodynamic effects in antifungal treatment strategies
Andrew J. Ullmann, Würzburg, DE
Ursula Theuretzbacher, Vienna, AT

This educational workshop has been arranged with AIDA (FP7 project  „Preserving old antibiotics for the future“):

Colistin use in clinical practice

Faculty: M. Paul, J.W. Mouton, W. Couet, Y. Carmeli

Interested in seeing more? Here is the list of prior events that I’ve presented at and/or organized.